Perspective Therapeutics, Inc.

Contributing Author

Recent Articles by Perspective Therapeutics, Inc.

Apr-02	Perspective Therapeutics to Participate in Upcoming Investor Conferences CATX GlobeNewswire
Mar-17	Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the AACR Annual Meeting 2026 CATX -5.17% GlobeNewswire
Mar-16	Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results CATX GlobeNewswire
Feb-17	Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results CATX GlobeNewswire
Feb-02	Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants CATX +33.51% GlobeNewswire
Jan-12	Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference CATX -15.14% GlobeNewswire
Jan-09	Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium CATX GlobeNewswire
Dec-18	Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference CATX GlobeNewswire
Dec-04	Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium CATX +8.14% GlobeNewswire
Nov-20	Perspective Therapeutics to Participate in Upcoming December Conferences CATX -7.83% GlobeNewswire
Nov-10	Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results CATX GlobeNewswire
Oct-31	Perspective Therapeutics to Participate in Upcoming November Conferences CATX GlobeNewswire
Oct-24	Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results CATX GlobeNewswire
Oct-20	Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-a-NET at the ESMO Congress 2025 CATX -28.95% GlobeNewswire
Oct-02	Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-a Positive Solid Tumors CATX GlobeNewswire
Sep-15	Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma CATX GlobeNewswire
Sep-04	Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer CATX GlobeNewswire
Sep-03	Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors CATX GlobeNewswire
Aug-26	Perspective Therapeutics to Participate in Upcoming September Conferences CATX GlobeNewswire
Aug-13	Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results CATX GlobeNewswire
Jul-24	Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ESMO Congress 2025 CATX GlobeNewswire
Jul-15	Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results CATX GlobeNewswire
Jun-21	Perspective Therapeutics Commences Recruitment for [212Pb]VMT-a-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial CATX GlobeNewswire
Jun-21	Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting CATX GlobeNewswire
May-30	Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-a-NET at the 2025 ASCO Annual Meeting CATX -7.00% CATX GlobeNewswire
May-12	Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results CATX +6.81% GlobeNewswire

Perspective Therapeutics, Inc.

Recent Articles by Perspective Therapeutics, Inc.

Upgrade your Finviz experience